Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Paragon Care Limited ( (AU:PGC) ) has provided an update.
Paragon Care Limited’s Annual Report for 2025 highlights its position as a diversified healthcare leader in the Asia Pacific, emphasizing its commitment to simplifying and enhancing healthcare accessibility. The report underscores the company’s strategic growth following its merger with Clifford Hallam and its dedication to environmental, social, and governance (ESG) principles, which are crucial for its stakeholders and industry positioning.
The most recent analyst rating on (AU:PGC) stock is a Buy with a A$0.50 price target. To see the full list of analyst forecasts on Paragon Care Limited stock, see the AU:PGC Stock Forecast page.
More about Paragon Care Limited
Paragon Care Limited is a leading healthcare distributor and manufacturer in the Asia Pacific region. The company offers a wide range of products including pharmaceuticals, capital equipment, diagnostics, medical consumables, devices, and complementary medicines. Established in Australia in 1918, Paragon Care has grown significantly, notably through its 2024 merger with Clifford Hallam, and is now an ASX-listed entity focused on making healthcare more accessible across the region.
Average Trading Volume: 418,090
Technical Sentiment Signal: Sell
Current Market Cap: A$471.8M
Learn more about PGC stock on TipRanks’ Stock Analysis page.